How many medicines do patients with heart failure need?
Parmley
W W
WW
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000378:metabolism; D004077:Digoxin / Q000627:therapeutic use; D004195:Disease Models, Animal; D004232:Diuretics / Q000627:therapeutic use; D016232:Endothelins / Q000037:antagonists & inhibitors; D000068800:Etanercept; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D051379:Mice; D008822:Mice, Transgenic; D015260:Neprilysin / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D016207:Cytokines; D004232:Diuretics; D016232:Endothelins; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D013148:Spironolactone; D004077:Digoxin; D015260:Neprilysin; D000068800:Etanercept